Adjuvant mitotane for adrenocortical cancer--a recurring controversy.
作者信息
Huang Hui, Fojo Tito
机构信息
Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
出版信息
J Clin Endocrinol Metab. 2008 Oct;93(10):3730-2. doi: 10.1210/jc.2008-0579.
Abstract
摘要
相似文献
1
Adjuvant mitotane for adrenocortical cancer--a recurring controversy.
J Clin Endocrinol Metab. 2008 Oct;93(10):3730-2. doi: 10.1210/jc.2008-0579.
2
Adjuvant mitotane for adrenocortical cancer--working through uncertainty.
J Clin Endocrinol Metab. 2009 Jun;94(6):1879-80. doi: 10.1210/jc.2009-0120.
3
Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report.
Therapie. 2015 Nov-Dec;70(6):545-6. doi: 10.2515/therapie/2015043. Epub 2015 Aug 4.
4
[Mitotane in the treatment of adrenal carcinoma].
Duodecim. 2010;126(17):2040-6.
5
Mitotane treatment for adrenocortical carcinoma: an overview.
Minerva Endocrinol. 2012 Mar;37(1):9-23.
6
Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
J Clin Endocrinol Metab. 1998 Sep;83(9):3100-3. doi: 10.1210/jcem.83.9.5113.
7
Adjuvant mitotane treatment for adrenocortical carcinoma.
N Engl J Med. 2007 Jun 7;356(23):2372-80. doi: 10.1056/NEJMoa063360.
8
Adjuvant mitotane therapy of adrenal cancer - use and controversy.
N Engl J Med. 2007 Jun 7;356(23):2415-8. doi: 10.1056/NEJMe078087.
9
Adjuvant mitotane in adrenocortical carcinoma.
N Engl J Med. 2007 Sep 20;357(12):1258-9; author reply 1259.
10
Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
J Clin Endocrinol Metab. 2013 Dec;98(12):4759-67. doi: 10.1210/jc.2013-2281. Epub 2013 Sep 20.
引用本文的文献
1
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
Lancet Diabetes Endocrinol. 2023 Oct;11(10):720-730. doi: 10.1016/S2213-8587(23)00193-6. Epub 2023 Aug 21.
2
A Revised Version of the TNM Classification Leads to Optimized Predictive Performance in Patients with Adrenocortical Carcinoma.
Horm Metab Res. 2023 Apr;55(4):227-235. doi: 10.1055/a-2042-2431. Epub 2023 Feb 24.
3
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question.
J Pers Med. 2021 Apr 4;11(4):269. doi: 10.3390/jpm11040269.
4
Long-term outcomes in patients with advanced adrenocortical carcinoma after image-guided locoregional ablation or embolization.
Cancer Med. 2021 Apr;10(7):2259-2267. doi: 10.1002/cam4.3740. Epub 2021 Mar 9.
5
Antineoplastic Effect of a Combined Mitotane Treatment/Ionizing Radiation in Adrenocortical Carcinoma: A Preclinical Study.
Cancers (Basel). 2019 Nov 9;11(11):1768. doi: 10.3390/cancers11111768.
6
Giant nonfunctioning adrenal tumors: two case reports and review of the literature.
J Med Case Rep. 2018 Nov 10;12(1):335. doi: 10.1186/s13256-018-1876-8.
7
Progress in Endocrine Neoplasia.
Clin Cancer Res. 2016 Oct 15;22(20):4981-4988. doi: 10.1158/1078-0432.CCR-16-0384.
8
Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.
Horm Cancer. 2016 Dec;7(5-6):345-355. doi: 10.1007/s12672-016-0273-2. Epub 2016 Sep 8.
9
Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).
J Endocrinol Invest. 2016 Jan;39(1):103-21. doi: 10.1007/s40618-015-0349-9. Epub 2015 Jul 14.
10
Management of adrenal cancer: a 2013 update.
J Endocrinol Invest. 2014 Mar;37(3):207-17. doi: 10.1007/s40618-013-0049-2.
本文引用的文献
1
Adjuvant mitotane in adrenocortical carcinoma.
N Engl J Med. 2007 Sep 20;357(12):1256-7; author reply 1259. doi: 10.1056/NEJMc076267.
2
Adjuvant mitotane treatment for adrenocortical carcinoma.
N Engl J Med. 2007 Jun 7;356(23):2372-80. doi: 10.1056/NEJMoa063360.
3
Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.
Cancer. 2001 Sep 15;92(6):1385-92. doi: 10.1002/1097-0142(20010915)92:6<1385::aid-cncr1461>3.0.co;2-2.
4
Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.
J Clin Endocrinol Metab. 2000 Jun;85(6):2234-8. doi: 10.1210/jcem.85.6.6619.
5
The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring.
Eur J Cancer Clin Oncol. 1984 Jan;20(1):47-53. doi: 10.1016/0277-5379(84)90033-6.
6
Adrenal cortical carcinoma. Clinical features of 138 patients.
Am J Med. 1966 Oct;41(4):572-80. doi: 10.1016/0002-9343(66)90219-1.
7
Complexing of DDT and o,p'DDD with adrenal cytochrome P-450 hydroxylating systems.
J Steroid Biochem. 1973 Nov;4(6):585-91. doi: 10.1016/0022-4731(73)90033-2.
8
Mitotane use in inoperable adrenal cortical carcinoma.
JAMA. 1973 Mar 5;223(10):1109-12.
9
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
Cancer. 1978 Nov;42(5):2177-81. doi: 10.1002/1097-0142(197811)42:5<2177::aid-cncr2820420514>3.0.co;2-x.
Zotero 插件